Press Release regarding Celebrex

Celebrex: Lawyer: Monheit Law: Side Effects: Heart Attack: 200mg Celebrex

According to a clinical trial conducted by the National Cancer Institute (NCI) and Pfizer, Inc., patients taking 400 mg of the drug twice daily had a 3.4 times greater risk of cardiovascular events compared to placebo. For patients in the trial taking 200 mg. twice daily, the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months.

These findings are similar to recent results from a study of Vioxx (rofecoxib), another drug in the same class. Vioxx was recently voluntarily recalled by Merckin September. Another drug in this class, Bextra (valdecoxib) has shown an increased risk for CV events in patients after heart surgery. Bextra and Celebrex are the only two selective COX-2 agents currently on the U.S. market.

While Pfizer announced today that it would halt advertising of the drug, it appears they had little choice in that decision. The Food and Drug Administration said on Friday that it was considering regulatory measures that could include severe label warnings or even requiring that the drug be withdrawn in the United States.

"Pfizer will inevitably have to recall Celebrex," Mr. Methvin said, "and I believe they are making a careless decision in not doing so immediately."

Andy Birchfield, Beasley Allen's lead Celebrex Litigation attorney, is spearheading the review of 383 cases, having filed 53 of those cases against Pfizer dating back to 2000.

For more information visit the Celebrex Legal Resource Site or contact:

Andy Birchfield, Attorney Beasley, Allen, Crow, Methvin, Portis & Miles, P.C. 1-800-898-2034 toll free 1-334-954-7555 fax andy.birchfield@beasleyallen.com

Online Media Contact: Jayme Yarroch 1-800-898-2343 toll free jayme.yarroch@beasleyallen.com Beasley Allen Law Firm Celebrex Lawsuit Information

Ask Monheit Law, "Do I have a Celebrex Case?"

For more information, contact:
Michael Monheit, Esquire, Monheit Law, PC